Immune cell combined tumor treatment medicine and preparation method thereof
The invention relates to the technical field of medicine preparation, and discloses an immune cell combined tumor treatment medicine and a preparation method thereof, the immune cell combined tumor treatment medicine comprises the following raw materials: 4-10 parts of a palbolizumab inhibitor, 6-10 parts of a PD-L1 immune checkpoint inhibitor, 4-8 parts of an irpizumab inhibitor, 5-10 parts of a tumor vaccine and a traditional Chinese medicine extract component, the traditional Chinese medicine extract component is prepared from the following raw materials in parts by weight: 8 to 16 parts of artemisinin, 10 to 16 parts of South African Manchurian rose, 12 to 20 parts of realgar, 10 to 18 parts of lucid ganoderma and 8 to 15 parts of radix angelicae sinensis, the artemisinin is extracted from tender leaves of a methyl artemisia apiacea plant in a flowering stage, and the South African Manchurian rose adopts rhizome parts of the South African Manchurian rose plant. Arsenic removal pretreatment is adopted before the realgar is used as the medicine, and drying pretreatment is adopted before the lucid ganoderma and the radix angelicae sinensis are used as the medicine. The oral western medicine and the oral traditional Chinese medicine extract are matched for use, so that the inhibition effect of an immune system on cancer cells is released, the tumor treatment period is effectively shortened, and meanwhile, the tumor treatment effect is improved..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Europäisches Patentamt - (2023) vom: 29. Dez. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
WANG HONGLIANG [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Sonstige Themen: |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2023-12-29, Last update posted on www.tib.eu: 2024-04-29, Last updated: 2024-05-03 |
|---|
| Patentnummer: |
CN117298282 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA000573426 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA000573426 | ||
| 003 | DE-627 | ||
| 005 | 20240503105625.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240315s2023 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA000573426 | ||
| 035 | |a (EPA)CN117298282 | ||
| 035 | |a (EPA)89237116 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a WANG HONGLIANG |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Immune cell combined tumor treatment medicine and preparation method thereof |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2023-12-29, Last update posted on www.tib.eu: 2024-04-29, Last updated: 2024-05-03 | ||
| 520 | |a The invention relates to the technical field of medicine preparation, and discloses an immune cell combined tumor treatment medicine and a preparation method thereof, the immune cell combined tumor treatment medicine comprises the following raw materials: 4-10 parts of a palbolizumab inhibitor, 6-10 parts of a PD-L1 immune checkpoint inhibitor, 4-8 parts of an irpizumab inhibitor, 5-10 parts of a tumor vaccine and a traditional Chinese medicine extract component, the traditional Chinese medicine extract component is prepared from the following raw materials in parts by weight: 8 to 16 parts of artemisinin, 10 to 16 parts of South African Manchurian rose, 12 to 20 parts of realgar, 10 to 18 parts of lucid ganoderma and 8 to 15 parts of radix angelicae sinensis, the artemisinin is extracted from tender leaves of a methyl artemisia apiacea plant in a flowering stage, and the South African Manchurian rose adopts rhizome parts of the South African Manchurian rose plant. Arsenic removal pretreatment is adopted before the realgar is used as the medicine, and drying pretreatment is adopted before the lucid ganoderma and the radix angelicae sinensis are used as the medicine. The oral western medicine and the oral traditional Chinese medicine extract are matched for use, so that the inhibition effect of an immune system on cancer cells is released, the tumor treatment period is effectively shortened, and meanwhile, the tumor treatment effect is improved. | ||
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a CHEN HUI |e verfasserin |4 aut | |
| 700 | 0 | |a TIAN HUI |e verfasserin |4 aut | |
| 700 | 0 | |a LIU FANLING |e verfasserin |4 aut | |
| 700 | 0 | |a NIU ANJIAN |e verfasserin |4 aut | |
| 700 | 0 | |a SONG SHENGJIE |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2023) vom: 29. Dez. |
| 773 | 1 | 8 | |g year:2023 |g day:29 |g month:12 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/89237116/publication/CN117298282A1?q=CN117298282 |x 0 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 29 |c 12 | ||